5 October 2026 AstraZeneca completes equity investment in Summit Therapeutics AstraZeneca today announced the successful completion of its $2 billion equity investment in Summit Therapeutics....
02 October 2026 AstraZeneca and Daiichi Sankyo announce clinical collaboration with Summit Therapeutics to evaluate Datroway in combination with ivonescimab across multiple tumour types Builds on recently announced clinical collaboration between AstraZeneca and Summit to advance leading ADC combination strategy in cancer AstraZeneca and Daiichi Sankyo have...
1 October 2026 Notification of Admission of Further Securities to Trading (PRM 1.6.4R) The following notification is made in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R....
1 October 2026 Total Voting Rights The following notification is made in accordance with the UK Financial Conduct Authority’s Disclosure and Transparency Rule 5.6.1. As at 30 September 2026 the issued share capital of AstraZeneca PLC with voting rights is 1,551,053,289 ordinary shares of US$0.25. No shares are held in Treasury....
29 September 2026 AstraZeneca announces strategic equity investment and clinical collaboration with Summit Therapeutics to advance leading ADC combination strategy in cancer Clinical collaboration will evaluate sonesitatug vedotin, a Claudin-18.2 ADC, with ivonescimab, a first-in-class PD-1/VEGF bispecific, in gastrointestinal cancers Planned broader...
23 September 2026 Trixeo approved in the EU for the maintenance treatment of asthma Trixeo is the first and only triple-combination therapy approved in the EU for patients 12 years and older, independent of exacerbation history AstraZeneca's fixed-dose triple-combination Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate or BGF...
21 September 2026 Klygefa (gefurulimab) recommended for approval in the EU by CHMP for the treatment of adults with generalised myasthenia gravis (gMG) Recommendation based on PREVAIL Phase III trial demonstrating statistically significant and clinically meaningful improvement in Myasthenia Gravis Activities of Daily Living score If approved, Klygefa will...
21 September 2026 Enhertu recommended for approval in the EU by CHMP as adjuvant treatment for patients with residual disease after neoadjuvant treatment for HER2-positive early breast cancer Based on DESTINY-Breast05 Phase III trial which showed Enhertu reduced the risk of invasive disease recurrence or death by 53% vs....
18 September 2026 Transaction by Person Discharging Managerial Responsibilities AstraZeneca PLC (the Company) announces that it was notified on 16 September 2026 that Pascal Soriot, Chief Executive Officer of the Company, purchased 60,000 of the Company's ordinary shares of $0.25 each (Ordinary Shares) on 14 September 2026, as set out below....
15 September 2026 Transaction by Person Discharging Managerial Responsibilities AstraZeneca PLC (the Company) announced that, on 14 September 2026, Dr Aradhana Sarin, Chief Financial Officer of the Company, acquired 73 of the Company's ordinary shares of $0.25 each (Ordinary Shares) following the vesting of certain dividend equivalent awards accrued in...
15 September 2026 Transaction by Person Discharging Managerial Responsibilities AstraZeneca PLC (the Company) announces that it was notified on 14 September 2026 that Michel Demaré, Non-Executive Chair of the Board, purchased 2,500 of the Company's ordinary shares of $0.25 each (Ordinary Shares) on 14 September 2026, as set out below....
This announcement contains inside information 14 September 2026 Update on SERENA-4 Phase III trial of Etcamah in combination with palbociclib in upfront 1st-line advanced ER-positive breast cancer SERENA-4 trial did not meet primary objective of statistically significant improvement in progression-free survival, however a numerical improvement was observed...
8 September 2026 Imfinzi plus Imdelltra demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer Imfinzi is the first and only immunotherapy in combination with a bispecific T-cell engager to show survival benefit in this setting...
07 September 2026 Etcamah in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer Approval based on SERENA-6 Phase III trial results which showed combination reduced the risk of disease progression or death by 56% in patients with an emergent ESR1 tumour mutation Innovative treatment strategy has potential...
1 September 2026 Notification of Admission of Further Securities to Trading (PRM 1.6.4R) The following notification is made in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R....
1 September 2026 Total Voting Rights The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 August 2026 the issued share capital of AstraZeneca PLC with voting rights is 1,551,043,461 ordinary shares of US$0.25. No shares are held in Treasury....
1 September 2026 Admission to Trading - €2.55 billion bond offering In accordance with the Financial Conduct Authority's Prospectus Rules: Admission to Trading on a Regulated Market (PRM) sourcebook 1.5.2 and 1.5.3R, AstraZeneca PLC announces that its wholly owned subsidiary AstraZeneca Finance LLC notifies the market that debt securities have been admitted...
01 September 2026 Enhertuplus pertuzumab approved in the EU as first new regimen in more than a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer Based on DESTINY-Breast09 Phase III trial which showed AstraZeneca and Daiichi Sankyo's Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% vs....
1 September 2026 Non-Executive Board Appointment AstraZeneca PLC announced today that Wan Ling Martello has been appointed as Non-Executive Director with effect from 1 September 2026. Wan Ling will become a member of the Audit Committee on appointment to the Board....
01 September 2026 AstraZeneca completes global license agreement for oral EGFR inhibitor Zegfrovy for lung cancer AstraZeneca today announced the successful completion of the previously announced exclusive license agreement (https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-licenses-novel-egfr-inhibitor.html) with Dizal Pharmaceutical...
1 September 2026 Tagrisso plusOrpathysdemonstrated statistically significant and highly clinically meaningful improvement in progression-free survival in 1st-line MET-overexpressing EGFR-mutated lung cancer Results of SANOVO Phase III trial in China build on established success of global SAFFRON and China SACHI trials, extending clinical value of the...
27 August 2026 Tezspire demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints Statistically significant and clinically meaningful disease and symptom improvements compared to placebo maintained through week 52 Efficacy in a third epithelial-driven inflammatory disease supports broad...
25 August 2026 AstraZeneca prices €2.55 billion bond offering AstraZeneca PLC (the Company) announces that, on 24 August 2026, its wholly owned subsidiary AstraZeneca Finance LLC, successfully priced four tranches of Eurobonds totalling €2.55 billion (the Offering)....
19 August 2026 Transaction by Person Discharging Managerial Responsibilities AstraZeneca PLC (the Company) announced that, on 17 August 2026, an award of the Company's ordinary shares of $0.25 each (Ordinary Shares) vested to the Company's Chief Financial Officer, Dr Aradhana Sarin, under the AstraZeneca Performance Share Plan (the AZPSP)....
17 August 2026 Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial AstraZeneca and Daiichi Sankyo's Enhertu is the first and only HER2-directed medicine to improve...
17 August 2026 Update on eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer AstraZeneca is discontinuing the eVOLVE-Lung02 Phase III trial evaluating volrustomig in combination with chemotherapy as a 1st-line therapy compared to pembrolizumab and chemotherapy in patients with metastatic non-small cell...
17 August 2026 Tagrisso plus Orpathys demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on Tagrisso First global Phase III trial to show significant progression-free and overall survival benefits in this setting SAFFRON trial results...
3 August 2026 Notification of Admission of Further Securities to Trading (PRM 1.6.4R) The following notification is made in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R....
3 August 2026 Total Voting Rights The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 July 2026 the issued share capital of AstraZeneca PLC with voting rights is 1,551,033,389 ordinary shares of US$0.25. No shares are held in Treasury....
31 July 2026 Datroway approved in the EU as only TROP2-directed medicine with overall survival benefit for the 1st-line treatment of patients with metastatic TNBC who are not candidates for immunotherapy Approval based on TROPION-Breast02 Phase III trial results where AstraZeneca and Daiichi Sankyo's Datroway showed a statistically significant and...
27 July 2026 Update on Phase III trial of Ultomiris in adults and adolescents with thrombotic microangiopathy after haematopoietic stem cell transplant High-level results from the ALXN1210-TMA-313 Phase III clinical trial showed that Ultomiris (ravulizumab) did not achieve statistical significance for the primary endpoint of event-free survival through 26...
27 July 2026 Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers Results provide opportunity to expand CLDN18.2 positivity to ≥25% expression, representing approximately 60% of patients in this setting...
27 July 2026 AstraZeneca results: H1 and Q2 2026 Growth momentum continues. On track to deliver ambition of $80 billion in Total Revenue in 2030 Revenue and EPS summary [][][] H1 2026 % Change Q2 2026 % Change $m Actual CER[1] $m Actual CER - Product Sales 28,896 8 5 14,510 5 4 - Alliance Revenue 1,699 31 29 874 34 33 Product Revenue 30,595 9 6 15,384 6 5...
23 July 2026 Etcamah (camizestrant) in combination with a CDK4/6 inhibitor approved in the EU for 1st-line advanced ER-positive breast cancer Approval based on SERENA-6 Phase III trial results which showed combination reduced the risk of disease progression or death by 56% in patients with an emergent ESR1 tumour mutation First and only next-generation oral...
14 July 2026 AstraZeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical Complements AstraZeneca’s leading portfolio of medicines targeting EGFR mutations Zegfrovy is approved in the US and China to treat lung cancer patients whose tumours carry exon 20 insertion mutations...